While the majority of completed trials for CB2-targeted agonists have focused on various types of pain, with a few studying cystic fibrosis or autoimmune disorders, at writing trials have been initiated for Alzheimer’s disease (AD), arterial disease, and cancer anorexia, which are previously unexplored indications. This evidence concerns the gene CNR2 and Alzheimer disease.